FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS mutant NSCLC patients in a Phase 1 study
AACR Annual Meeting
International Congress on Targeted Anticancer Therapies
Keystone Symposium – New Frontiers in Understanding Tumor Metabolism
Keystone Symposium – New Frontiers in Understanding Tumor Metabolism
EORTC-NCI-AACR International Conference
EORTC-NCI-AACR International Conference
Menlo Park, California, November 2, 2015. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics in oncology, announced today that
Menlo Park, California, September 17, 2015. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics in oncology, announced today that